GENE ONLINE|News &
Opinion
Blog

COVID-19
The U.S. COVID-19 Public Health Emergency Ends in May, but FDA’s EUA Authority Remains
2023-02-01
Novavax Begins Phase 2 For COVID-19/Influenza Combination And Stand-Alone Flu Shots
2023-01-03
CDC Warns Of “Tripledemic” Winter Amid Rising Flu And RSV Cases
2022-11-14
Sanofi, GSK Secure European COVID-19 Booster Approval, AstraZeneca Withdraws U.S. Application
2022-11-10
AstraZeneca’s COVID-19 Vaccine Finally Wins Full Authorization in the European Union
2022-11-01
Pfizer to Raise COVID-19 Vaccine Prices Amidst Rising Flu Cases
2022-10-24
Pfizer/BioNTech’s Omicron Booster Snags Another FDA Emergency Use Authorization
2022-10-12
Novavax Prototype COVID-19 Vaccine Data Support Homologous and Heterologous Boosting and Suggest Benefit Against Variants
2022-10-12
Pfizer Pledges 6 million COVID-19 Treatment Courses to Global Fund
2022-09-22
AstraZeneca’s Treatment for COVID-19 Wins European Approval
2022-09-20
The COVID-19 Pandemic: Is Omicron the Last Variant?
2022-09-16
WHO Urges Action After Model Suggests Over 17 Million Europeans Experienced Long COVID
2022-09-14
U.S. Government to No Longer Provide Free COVID-19 Vaccines
2022-08-31
FDA Approves Both Moderna’s and Pfizer/BioNTech’s Omicron Bivalent Vaccines in One Day
2022-08-31
AstraZeneca’s Role in COVID-19 Slows Down as World Looks to mRNA Vaccines
2022-08-31
1 2 3 26
LATEST
NDA for Biogen-Sage’s Zuranolone Accepted by FDA, Marking Another Step Forward in Depression Drug Development
2023-02-07
BMS Returns $475 Million Cancer Asset To Dragonfly Therapeutics
2023-02-07
FDA Expands Approval For Takeda’s Takhzyro To Prevent Hereditary Angioedema Attacks
2023-02-06
Abbott’s New Technologies for Arrhythmia Treatment Secure FDA and European Approval
2023-02-04
First Human Trial for Marburg Virus Vaccine Reports Success
2023-02-03
Karuna Licenses Goldfinch’s Mood Disorder Candidates For Potential $535 Million
2023-02-03
Novel Bioengineered Wearable Edgeless Skin Brings Hope to Revolutionize Plastic and Reconstructive Surgery
2023-02-03
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!